Mugglehead
Subscribe

Unicycive Therapeutics reports US$59M ahead of March FDA target

The kidney-drug developer expects its cash and securities to last beyond 2027, including spending for a potential OLC launch.

Adrian Kessler·
An unmarked dissolution-testing apparatus stands in a generic pharmaceutical quality-control laboratory.
An unmarked dissolution-testing apparatus in a generic pharmaceutical quality-control laboratory. Illustration: Mugglehead, generated with AI.

Funding is expected to last beyond 2027 as Unicycive Therapeutics, Inc. NASDAQUNCY reported US$59 million in cash and securities on Monday. The estimate includes potential launch spending for oxylanthanum carbonate, which has an FDA target action date of March 25, 2027.

The unaudited cash, cash equivalents and marketable securities balance was measured at Sept. 30. The resubmitted drug application remains under review after a June refusal tied to deficiencies at the original manufacturing vendor, according to the company. The FDA accepted the resubmission in October.

Unicycive is a Mountain View, Calif., biotechnology developer preparing oxylanthanum carbonate, or OLC, an investigational phosphate binder for elevated phosphorus in patients with chronic kidney disease on dialysis.

The last available NASDAQUNCY close was US$3.55 at 4:00 p.m. EST on Nov. 13, before Monday’s results. The March target date was announced in October; the new quarterly report sets out the funding available ahead of that decision.

Launch Preparations Lift Spending

In the third quarter of 2026, the loss attributable to common shareholders widened to US$7 million from US$6 million a year earlier. Unicycive attributed the increase primarily to commercial launch expenses.

General and administrative expenses reached US$6.6 million in the 2026 quarter, compared with US$4.4 million a year earlier. Commercial launch preparation accounted for a US$1.4 million increase, while research and development spending fell as development costs declined.

Unicycive plans to bring commercial leaders aboard in the first quarter of 2027 and hire a sales force if OLC wins approval. It is discussing launch plans with dialysis organizations and preparing a patient-access support hub.

“With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch,” chief executive Shalabh Gupta said.

Read more: Milestone Pharmaceuticals plans 30 per cent expense cut to extend cash runway

According to Unicycive, the June response raised no concerns about clinical efficacy or safety data and requested no additional company data. The resubmission includes manufacturing data from a new vendor whose facility received a “No Action Indicated” classification after its March 2024 FDA inspection.

Unicycive does not know whether the FDA will conduct a preapproval inspection of that facility. Its runway estimate includes increased launch expenses if approval arrives, but manufacturing review remains part of the pending application.

Dialysis Payments Change In January

The commercial market includes Ardelyx Inc. NASDAQARDX, which reported third-quarter Xphozah revenue of US$29.2 million in its Nov. 3 results. Sales grew seven per cent from a year earlier.

Akebia Therapeutics, Inc. NASDAQAKBA reported Auryxia revenue of US$20 million in its Nov. 5 quarterly update, compared with US$42.5 million a year earlier. Akebia expects that product’s 2026 revenue to decline because of generic competition and pricing pressure.

The Centers for Medicare & Medicaid Services finalized a US$12.85 per-treatment addition for phosphate binders in the dialysis payment bundle on Oct. 28. Rule CMS-1846-F takes effect Jan. 1, 2027.

Unicycive believes OLC could qualify for two years of separate transitional reimbursement at full average sales price. That remains conditional on FDA approval, the agency’s application classification and CMS confirmation of eligibility.

The FDA alone decides the application’s classification. Unicycive’s reimbursement case rests on its view that OLC contains a new active ingredient even though lanthanum has previously been approved.

Read more: Belite Bio reports US$774M in liquidity ahead of tinlarebant FDA date

The next FDA target action date is March 25, 2027, when the agency is scheduled to act on OLC’s resubmitted application. Approval would allow Unicycive to proceed with the launch covered by its spending forecast.

More in Health & Science

View all